Pfizer Inc. has divulged 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17- β-HSD 13) inhibitors and/or degraders reported to be useful for the treatment of hepatocellular carcinoma, biliary cirrhosis, hepatitis B and hepatitis C viral infections, alcoholic and nonalcoholic fatty liver disease, among others.
Virginia Commonwealth University has identified cholestenoic acid derivatives reported to be useful for the treatment of cancer, sepsis, atherosclerosis and nonalcoholic fatty liver disease (NAFLD; metabolic dysfunction-associated steatotic liver disease [MASLD]).
Synedgen Inc. has completed IND-enabling studies for its lead candidate, MIIST-305, which is being developed for ulcerative colitis and as a medical countermeasure for gastrointestinal acute radiation syndrome. Within a year, Synedgen plans to file an IND application for MIIST-305 and initiate a phase I study to support both programs.
Ochre Bio Ltd. has established a partnership with Boehringer Ingelheim Pharma GmbH & Co. KG focused on the discovery and development of novel first-in-class regenerative treatments for chronic liver diseases, such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
New York University has described protein spinster homolog 2 (SPNS2) inhibitors reported to be useful for the treatment of acute lung injury, autoimmune disease, colitis, Alzheimer’s disease, fibrosis, inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis.
Palisade Bio Inc. has completed its analysis evaluating ex vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for ulcerative colitis.
Scientists from Shanghai Jiao Tong University and affiliated organizations have discovered novel GPR183 antagonists as potential therapeutic candidates for the treatment of inflammatory bowel disease (IBD). With the aim of improving the pharmacokinetic (PK) and safety profile of previously reported oxysterol receptor GPR183 antagonists, structural optimization of the reference antagonist NIBR-189 was conducted.
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease, shows different occurrence between sexes, being less prevalent in premenopausal women than in men or postmenopausal women.
Parvus Therapeutics Inc. has entered into an exclusive worldwide collaboration and option agreement with Abbvie Inc. for the development and commercialization of novel treatments for inflammatory bowel disease (IBD), utilizing Parvus’ Navacim regulatory T-cell (Treg) immune tolerization platform technology.
RSS
